Drugs / I-131-1095
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03939689 | May 2019 → Sep 2023 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Progenics Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I-131-1095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939689 ↗ |